Overview

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Status:
Completed

Trial end date:
2016-05-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines